Growth Hormone & Igf Research最新文献

{"title":"Serum IGF-I concentrations are low in female bodybuilders in the pre-contest phase","authors":"Diana Paula Pandochi Fernandes Monteiro ,&nbsp;Marcos Correa Jr ,&nbsp;Thomaz Talarico Neto ,&nbsp;Carlos Eduardo Martinelli Jr ,&nbsp;Hugo Tourinho Filho","doi":"10.1016/j.ghir.2021.101420","DOIUrl":"10.1016/j.ghir.2021.101420","url":null,"abstract":"<div><p>Bodybuilding involves athletes performing a series of poses/postures on the stage so that they can be classified according to their best esthetic and physical appearance during the competition. In the weeks prior to the target competition, the athletes subject themselves to restrictive diets and different physical training methods, as well as using dietary supplementation<span><span><span> and, in some cases, anabolic steroids, to reduce body fat to low levels and maintain or increase muscle mass. On the other hand, it is known that physical training is a potent stimulator for releasing the components of the GH/IGF-I axis that are directly linked to the anabolic process. Based on these assumptions, this study aimed to verify the kinetics of IGF-I and of its </span>binding protein IGFBP-3 in female bodybuilders. Serum IGF-I and IGFBP-3 concentrations were recorded before and after standardized training sessions at two different times: in the initial phase (phase 1) and in the final phase of the pre-contest (phase 2) of a 12-week training season. It was possible to conclude that there was a significant reduction in serum IGF-I values at the end of the pre-contest phase that preceded the athletes' participation in a competition. With relation to the serum IGF-I and IGFBP-3 values measured before and after the standardized training session, it was only possible to verify significant changes in the IGF-I values in the initial phase of the pre-contest. It seems reasonable to suggest that the </span>caloric restriction used by bodybuilders may be related to the decrease in IGF-I values verified at the end of the pre-contest phase.</span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101420"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39290366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between circulating insulin-like growth factor-1 and blood pressure in adults: A systematic review and meta-analysis of observational studies","authors":"Lina Leng ,&nbsp;Yuling Xing ,&nbsp;Yi Liang ,&nbsp;Chang Wang ,&nbsp;Huijuan Ma","doi":"10.1016/j.ghir.2021.101416","DOIUrl":"10.1016/j.ghir.2021.101416","url":null,"abstract":"<div><h3>Objective</h3><p>Insulin-like growth factor 1 (IGF-1) is an important factor related to cardiovascular disease. In recent years, studies have shown the involvement of IGF-1 and blood pressure (BP). Nevertheless, the results were inconsistent. Thus, the purpose of this study was to systematically evaluate the associations of circulating IGF-1 levels with BP in adults.</p></div><div><h3>Methods</h3><p><span>Two reviewers independently searched and screened articles from the Pubmed, EMBASE, Cochrane Library, CNKI, and WANFANG databases up to May 2020. A total of 12 studies that reported the correlation coefficients between IGF-1, </span>systolic blood pressure<span> (SBP), and diastolic blood pressure (DBP) were included.</span></p></div><div><h3>Results</h3><p>IGF-1 was significantly correlated with SBP [<em>r</em> = −0.15; 95% CI = −0.21, −0.08; <em>P</em> &lt; 0.0001] and DBP [<em>r</em> = −0.10; 95% CI = −0.16, −0.05; <em>P</em> = 0.0004]. Subgroup analysis further revealed that the relationship between IGF-1 and BP was influenced by race and age.</p></div><div><h3>Conclusion</h3><p>Circulating IGF-1 was negatively correlated with SBP and DBP. Further researches are necessary to explore the pathogenesis of this relationship and to evaluate the role of IGF-1 in the treatment of hypertension.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101416"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101416","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39193475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNA-seq and nuclear proteomics provide insights into the lactation regulation mechanism of goat transfected IGF-I and GH recombinant vectors","authors":"Shaodong Fu ,&nbsp;Xuehuai Shen ,&nbsp;Xudong Wang ,&nbsp;Yilin Zhou ,&nbsp;Jinqiu Zhang ,&nbsp;Jinfeng Miao","doi":"10.1016/j.ghir.2021.101428","DOIUrl":"10.1016/j.ghir.2021.101428","url":null,"abstract":"<div><p><span><span>There exists little available information on the mechanisms of lactation<span><span> regulation until now. In order to explore the underlying mechanism, we injected IGF-I and GH recombinant<span> vectors into the mammary gland, then RNA-seq analysis and nuclear proteomics<span><span> were used for rapid high-throughput screening of DEGs and DEPs in the two groups linked to lactation regulation. KEGG analysis of 206 DEGs showed that the same 4 of top 10 enrichment pathways (ECM receptor interaction, protein digestion and absorption, focal adhesion and phagosome) involved in 4 co-expressed genes (IDO, </span>BTG1, ITGB6 and </span></span></span>keratin 83), the two groups enriched different metabolic pathways yet. Nuclear proteomics analysis showed 75 and 36 DEPs in the IGF-I and GH group respectively; Sixteen common proteins were identified between the IGF-I group and GH group, four of which (ALB, TPT1, CXXC-5 and ACTR2) significantly decreased and three of which (PRP1, PAG-9 and Hsp70) significantly increased. Similarly, DEPs in the two groups were enriched in same one of top 10 enrichment pathways (PI3K-Akt signaling pathway). Protein-protein interaction networks highlighted the contribution of </span></span>glycosphingolipid<span> biosynthesis, porphyrin and chlorophyll metabolism and the Jak-STAT signaling pathway to lactation regulation of GH and IGF</span></span><img><span><span>I. GH and IGF-I improve milk yield, which may be linked to important nodal proteins (ALB and ACTB). Our research advances the understanding of the mammary gland </span>transcriptome and nuclear proteomics during GH and IGF-I overexpression. Individual genes, proteins and pathways in this study point towards potential targets for lactation regulation.</span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101428"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101428","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39405054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GHRH expression plasmid improves osteoporosis and skin damage in aged mice","authors":"Rui Ye,&nbsp;Hai-long Wang,&nbsp;De-Wei Zeng,&nbsp;Ting Chen,&nbsp;Jia-Jie Sun,&nbsp;Qian-Yun Xi,&nbsp;Yong-Liang Zhang","doi":"10.1016/j.ghir.2021.101429","DOIUrl":"10.1016/j.ghir.2021.101429","url":null,"abstract":"<div><p><span>The hormone secretion of GHRH-GH-IGF-1 axis in animals was decreased as aging. These hormones play an important role in maintaining bone mass and bone structure, and also affect the normal structure and function of the skin. We used plasmid-based technology to deliver growth hormone releasing hormone (GHRH) to elderly mice. In the current study, 80 and 120 μg/kg pVAX-GHRH plasmid expression plasmid were injected into old mice, the serum GHRH and insulin-like growth factor-1(IGF-1) content were increased within three weeks (</span><em>P</em><span> &lt; 0.05). In the groups of 80 and 120 μg/kg plasmid, the content of procollagen type I N-terminal pro-peptide (PINP) in the serum was increased(</span><em>P</em><span> &lt; 0.05), and the content of C-terminal telopeptides of type I collagen (CTX-1) in the serum was reduced significantly (</span><em>P</em><span><span> &lt; 0.05). Furthermore, the expression of osteoprotegerin (OPG) and </span>osteocalcin (OCN) in the femur also was increased(</span><em>P</em> &lt; 0.05). The bone mineral density(BMD)、trabecular bone volume (BV/TV) and trabecular number(Tb.N) of mouse femur were increased significantly (<em>P</em> &lt; 0.05) and trabecular separation(Tb.Sp) was decreased(P &lt; 0.05). There were more trabecular bones in the bone marrow cavity and the trabecular bones are thicker in the groups of 80 and 120 μg/kg plasmid relative to control. The superoxide dismutase (SOD) content in the skin was increased(<em>P</em><span> &lt; 0.05), and the malondialdehyde (MDA) content was reduced significantly (</span><em>P</em> &lt; 0.05). Meanwhile, the skin moisture content also increased significantly(<em>P</em><span> &lt; 0.05). Moreover, the expression of matrix metalloproteinase 3(MMP3) and matrix metalloproteinase 9(MMP9) was decreased in the skin(</span><em>P</em><span> &lt; 0.05). The thickness of the dermis and epidermis of the skin had increased significantly(</span><em>P</em><span> &lt; 0.05). Skin structure is more dense and complete in the two groups. These results indicate that 80 and 120 μg/kg plasmid-mediated GHRH supplementation can improve osteoporosis and skin aging in aged mice.</span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101429"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39422998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult height and long-term outcomes after rhIGF-1 therapy in two patients with PAPP-A2 deficiency","authors":"Álvaro Martín-Rivada ,&nbsp;Vicente Barrios ,&nbsp;Guillermo Martínez Díaz-Guerra ,&nbsp;Jesús Pozo ,&nbsp;Gabriel Ángel Martos-Moreno ,&nbsp;Jesús Argente","doi":"10.1016/j.ghir.2021.101419","DOIUrl":"10.1016/j.ghir.2021.101419","url":null,"abstract":"<div><p>PAPP-A2 deficiency is a novel syndrome characterized by short stature due to low IGF bioactivity, skeletal abnormalities and decreased bone mineral density (BMD). Treatment with recombinant human IGF-1 (rhIGF-1) for 1 year demonstrated to increase growth velocity and BMD, without reported adverse effects, but data regarding the long-term efficacy and safety of rhIGF-1 administration in this entity has not yet been reported.</p><p>Two Spanish siblings with short stature due to a homozygous loss-of-function mutation in the <em>PAPP-A2</em> gene (p.D643fs25*) were treated with rhIGF-1 twice daily for six years. Growth velocity continued to increase and both patients achieved their target height. Free IGF-1 concentrations increased notably after rhIGF-1 administration, with serum IGFBP-3, IGFBP-5 and ALS levels also being higher during treatment. BMD was progressively normalized and an increase in lean mass was also noted during treatment. No episodes of hypoglycemia or any other adverse effects were documented. An increase in the growth of kidney and spleen length was observed in one of the patients.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101419"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101419","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39286017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials","authors":"Yan Sun ,&nbsp;Ying Xiong ,&nbsp;Yong Liang Meng ,&nbsp;Heitor O. Santos ,&nbsp;Felipe L. Athayde ,&nbsp;Ivan G.O. de Souza ,&nbsp;Ling Yang","doi":"10.1016/j.ghir.2021.101421","DOIUrl":"10.1016/j.ghir.2021.101421","url":null,"abstract":"<div><h3>Objective</h3><p>To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels.</p></div><div><h3>Methods</h3><p>A systematic comprehensive search was performed without language limitation up to 14 December 2020. We included only trials that assessed the effect of raloxifene on IGF-1 and IGFBP-3 in adults. Meta-analysis was performed using the Stata software (Stata Corp. College Station, Texas, USA).</p></div><div><h3>Results</h3><p><span>Seven arms were included, encompassing postmenopausal women with type 2 diabetes mellitus, postmenopausal women with breast cancer, healthy postmenopausal women, and healthy elderly men. Raloxifene therapy significantly reduced IGF-1 levels (WMD: −2.92 nmol/L, 95% CI: −3.49, −2.35, </span><em>p</em> &lt; 0.001) compared to placebo. Raloxifene dosage ˃60 mg/day (WMD: −3.29 ng/mL, 95% CI: −3.50 to −3.08, I² = 0.0%) decreased IGF-1 levels more than 60 mg/day (WMD: −2.29 ng/mL, 95% CI: −2.90 to −1.69, I² = 16%). Moreover, intervention duration ˃26 weeks (WMD: −3.48 ng/mL, 95% CI: −5.26 to −1.69, I² = 0.0%) reduced IGF-1 levels more than ˂26 weeks (WMD: −2.55 ng/mL, 95% CI: −3.31 to −1.79, I² = 92%). In contrast, overall results from the random-effects model did not suggest a significant change in IGFBP-3 levels upon raloxifene therapy.</p></div><div><h3>Conclusion</h3><p>Raloxifene therapy significantly reduced serum levels of IGF-1 levels but without changes in IGFPB-3 levels.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101421"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39305098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of milk and rapeseed protein on growth factors in 7–8 year-old healthy children – A randomized controlled trial","authors":"Benedikte Grenov,&nbsp;Anni Larnkjær,&nbsp;Christian Ritz,&nbsp;Kim F. Michaelsen,&nbsp;Camilla T. Damsgaard,&nbsp;Christian Mølgaard","doi":"10.1016/j.ghir.2021.101418","DOIUrl":"10.1016/j.ghir.2021.101418","url":null,"abstract":"<div><p>Objective: Milk protein may stimulate linear growth through insulin-like growth factor-1 (IGF-1). However, the effect of plant proteins on growth factors is largely unknown. This study assesses the effect of combinations of milk and rapeseed protein versus milk protein alone on growth factors in children.</p><p>Design: An exploratory 3-armed randomized, double-blind, controlled trial was conducted in 129 healthy 7–8 year-old Danish children. Children received 35 g milk and rapeseed protein (ratio 54:46 or 30:70) or 35 g milk protein per day for 4 weeks. The primary outcome was difference in IGF-1 changes between intervention groups after 4 weeks. Secondary outcomes included changes in IGF-1 after 1 week and changes in insulin-like growth factor binding protein-3 (IGFBP-3), IGF-1/IGFBP-3, insulin, height, weight and body composition after 1 and 4 weeks. Results were analysed by multiple linear mixed-effect models.</p><p>Results: There were no differences in changes of plasma IGF-1, insulin-like growth factor binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio or insulin between groups after 1 or 4 weeks based on 89 complete cases (<em>P</em> &gt; 0.10). IGF-1 increased by 13.7 (95% CI 9.7;17.7) ng/mL and 18.0 (14.0;22.0) ng/mL from baseline to week 1 and 4, respectively, a 16% increase during the intervention. Similarly, insulin increased by 31% (14; 50) and 33% (16; 53) from baseline to week 1 and 4. Fat-free mass index (FFMI) increments were higher with milk alone than rapeseed blends (<em>P</em> &lt; 0.05), coinciding with a trend towards a lower height increment. Body mass index increased within all groups (P &lt; 0.05), mainly due to an increase in FFMI (<em>P</em> &lt; 0.01).</p><p>Conclusion: There were no differences in changes of growth factors between the combinations of milk and rapeseed protein and milk protein alone in healthy, well-nourished children with a habitual intake of milk. Within groups, growth factors increased considerably. Future studies are needed to investigate how intakes of plant and animal proteins affect childhood growth.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101418"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39270906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The necessity of magnetic resonance imaging in the evaluation of pediatric growth hormone deficiency: Lessons from a large academic center","authors":"Leena Mamilly ,&nbsp;Amy L. Pyle-Eilola ,&nbsp;Monika Chaudhari ,&nbsp;Rohan K. Henry","doi":"10.1016/j.ghir.2021.101427","DOIUrl":"10.1016/j.ghir.2021.101427","url":null,"abstract":"<div><h3>Background</h3><p><span>Current guidelines indiscriminately recommend magnetic resonance imaging (MRI) of the pituitary gland<span> in pediatric </span></span>growth hormone deficiency (GHD). The relationship between abnormal MRI, most importantly a tumor, and peak GH levels is not well known.</p></div><div><h3>Methods</h3><p>In this retrospective chart review, pituitary MRI results of children, ages of 3–16 years with GHD were collected and divided into 3 groups according to peak stimulated GH levels; ≤5, 5–7.4 and 7.5–10 ng/mL, Groups A, B &amp; C respectively. Clinical and MRI findings were compared between the groups.</p></div><div><h3>Results</h3><p>A total of 399 children were included. Abnormal MRI was found in 36.9% of group A subjects, compared to group B (16.7%) and group C (17.0%), both <em>p</em><span> values =0.0002. Children with multiple pituitary hormonal deficiencies (MPHD) had a higher rate of abnormalities than those with isolated GHD. Children with isolated GHD were more likely to have abnormal MRI with peak GH level &lt; 5 ng/mL compared to those with levels, 5–7.4 &amp; 7.5–10 ng/mL. 4 children in group A had a craniopharyngioma. ROC analysis comparing peak GH levels with abnormal MRI findings showed an area under the curve (AUC) of 0.614 and 0.728 for IGHD and MPHD, respectively.</span></p></div><div><h3>Conclusion</h3><p>Although abnormal MRI was found in all 3 study groups, it was more likely at GH level &lt; 5 ng/mL and in children with MPHD. To avoid missing a tumor, the importance of imaging in children with GHD and peak GH levels &lt;5 ng/mL cannot be overemphasized.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101427"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39473342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutations in GH1 gene and isolated growth hormone deficiency (IGHD): A familial case of IGHD type I and systematic review","authors":"Qiuyue Li ,&nbsp;Zhenran Xu ,&nbsp;Miaoying Zhang ,&nbsp;Zhuhui Zhao ,&nbsp;Bijun Sun ,&nbsp;Lin Yang ,&nbsp;Wei Lu ,&nbsp;Feihong Luo ,&nbsp;Chengjun Sun","doi":"10.1016/j.ghir.2021.101423","DOIUrl":"10.1016/j.ghir.2021.101423","url":null,"abstract":"<div><h3>Background</h3><p><span>Isolated growth hormone deficiency (IGHD) due to mutations in </span><em>GH1</em> gene is a rare disease caused by deficient production of endogenous growth hormone (GH).</p></div><div><h3>Methods</h3><p><span><span>We reported the clinical manifestation and genetic diagnosis (whole exome sequencing [WES], </span>nested PCR<span> Sanger sequencing, and rtPCR) of a family with two children with IGHD type I. We conducted a </span></span>systematic review<span> of cases with IGHD and compared height, and treatment outcomes in subtypes of IGHD.</span></p></div><div><h3>Results</h3><p>The patients were siblings born of nonconsanguineous parents from the Chinese Han population. The siblings both presented significantly short stature without other apparent abnormalities. The patients carry compound heterozygous mutations in <em>GH1</em>: a deletion and c.456 + 1G &gt; A mutation that led to abnormal splicing. The systematic review identified 365 IGHD cases with <em>GH1</em><span> mutations. Among these patients, their body height was most severely impaired in patients<span> with IGHD type Ia, and the height standard deviation score decreased with the age of diagnosis in IGHD type Ia. Patients with IGHD type II had the longest duration of rhGH treatment, while patients with IGHD type Ib had the highest relative height improvement.</span></span></p></div><div><h3>Conclusion</h3><p>We identified two patients with IGHD type I caused by compound heterozygotic <em>GH1</em> deletion and splicing mutation. The analysis of previously published IGHD patients suggests differences in linear growth among subtypes of IGHD.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101423"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101423","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39297604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Course and outcomes of pregnancy in women treated for acromegaly: Discerning a contemporary cohort","authors":"Liza Das ,&nbsp;Pinaki Dutta ,&nbsp;Balamurugan Thirunavukkarasu ,&nbsp;Kirti Gupta ,&nbsp;Manjul Tripathi ,&nbsp;Prakamya Gupta ,&nbsp;Neelam Aggarwal ,&nbsp;Ashutosh Rai ,&nbsp;Bishan Dass Radotra ,&nbsp;Anil Bhansali ,&nbsp;Vanita Suri","doi":"10.1016/j.ghir.2021.101417","DOIUrl":"10.1016/j.ghir.2021.101417","url":null,"abstract":"<div><h3>Objective</h3><p>To analyze pregnancy course and outcomes in women treated for acromegaly and compare outcomes based on disease activity at the time of conception.</p></div><div><h3>Design</h3><p>Retrospective study.</p></div><div><h3>Patients</h3><p>Women with acromegaly diagnosed prior to or during pregnancy from 2010 to 2019, representing cases (14 pregnancies in 12 cases), were later stratified based on active (<em>n</em> = 5) or controlled disease (<em>n</em> = 9) at time of conception. Female acromegalic patients over the same period constituted the ‘acromegaly cohort’ (AC) (<em>n</em> = 75).</p></div><div><h3>Results</h3><p><span><span>All cases had macroadenomas with nadir GH of 15.06 ng/ml (IQR 9–30), IGF-I index of 3.04 (1.96–3.82), for which they had undergone </span>pituitary surgery<span>; except two patients diagnosed during pregnancy, who received pharmacotherapy followed by surgery 4 months postpartum. Adjuvant pharmacotherapy was required in 71.4% patients and radiotherapy in 35.7%. Pregnancy occurred at a median of 2 (0.8–5.1) years after surgery and 21.4% required assisted reproduction<span>. All had term delivery with normal APGAR except one case with gestational hypertension<span>, who delivered a preterm baby. None had congenital malformations. Despite higher baseline IGF-I, GH and tumor volume in those with pre-conceptional active acromegaly, materno-fetal outcomes were not different from those with controlled disease (</span></span></span></span><em>p</em> &gt; 0.05). Similar or greater proportion of cases had normal GH and no residual tumor postpartum, even in those with pre-conceptional active acromegaly.</p></div><div><h3>Conclusion</h3><p>The current study showed conducive outcomes of gestation in women treated for acromegaly and no higher rates of pregnancy parameters or complications than non-acromegaly pregnancies in the same population. Active acromegaly does not seem to have an adverse bearing on outcomes.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101417"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101417","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39191279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}